{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T09:30:57Z","timestamp":1771147857760,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.bone.2019.01.003","type":"journal-article","created":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T02:28:56Z","timestamp":1546568936000},"page":"60-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review"],"prefix":"10.1016","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8996-8760","authenticated-orcid":false,"given":"Nat","family":"Nasomyont","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey N.","family":"Hornung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine M.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8309-6321","authenticated-orcid":false,"given":"Halley","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2019.01.003_bb0005","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bone.2016.12.008","article-title":"Use of dual energy X-ray absorptiometry in pediatric patients","volume":"104","author":"Wasserman","year":"2017","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2019.01.003_bb0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000381713","article-title":"Efficacy and safety of bisphosphonate therapy in children with osteogenesis imperfecta: a systematic review","volume":"84","author":"Rijks","year":"2015","journal-title":"Horm. Res Paediatr."},{"issue":"12","key":"10.1016\/j.bone.2019.01.003_bb0015","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/jbmr.2567","article-title":"Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years","volume":"30","author":"Palomo","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"7","key":"10.1016\/j.bone.2019.01.003_bb0020","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00198-016-3515-9","article-title":"The management of osteoporosis in children","volume":"27","author":"Ward","year":"2016","journal-title":"Osteoporos. Int."},{"issue":"5","key":"10.1016\/j.bone.2019.01.003_bb0025","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.pmrj.2013.10.009","article-title":"Bisphosphonate treatment for children with disabling conditions","volume":"6","author":"Boyce","year":"2014","journal-title":"PM R"},{"issue":"5","key":"10.1016\/j.bone.2019.01.003_bb0030","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000365889","article-title":"The use of bisphosphonates in pediatrics","volume":"82","author":"Baroncelli","year":"2014","journal-title":"Horm. Res. Paediatr."},{"issue":"6","key":"10.1016\/j.bone.2019.01.003_bb0035","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00198-004-1731-1","article-title":"The efficacy of acute administration of pamidronate on the conservation of bone mass following severe burn injury in children: a double-blind, randomized, controlled study","volume":"16","author":"Klein","year":"2005","journal-title":"Osteoporos. Int."},{"issue":"3","key":"10.1016\/j.bone.2019.01.003_bb0040","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s00467-004-1790-8","article-title":"Pamidronate treatment of pediatric fracture patients on chronic steroid therapy","volume":"20","author":"Acott","year":"2005","journal-title":"Pediatr. Nephrol."},{"issue":"7","key":"10.1016\/j.bone.2019.01.003_bb0045","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/jbmr.1598","article-title":"Zoledronic acid improves bone mineral density in pediatric spinal cord injury","volume":"27","author":"Ooi","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"11","key":"10.1016\/j.bone.2019.01.003_bb0050","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1007\/s00198-012-1911-3","article-title":"The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy","volume":"23","author":"Sbrocchi","year":"2012","journal-title":"Osteoporos. Int."},{"issue":"9","key":"10.1016\/j.bone.2019.01.003_bb0055","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/1529-0131(200009)43:9<1960::AID-ANR6>3.0.CO;2-J","article-title":"Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study","volume":"43","author":"Bianchi","year":"2000","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.bone.2019.01.003_bb0060","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jocd.2014.01.007","article-title":"Pediatric position development conference: executive summary and reflections","volume":"17","author":"Gordon","year":"2013","journal-title":"J. Clin. Densitom."},{"issue":"4","key":"10.1016\/j.bone.2019.01.003_bb0065","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/acr.20171","article-title":"Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders","volume":"62","author":"Huber","year":"2010","journal-title":"Arthritis Care Res."},{"issue":"9418","key":"10.1016\/j.bone.2019.01.003_bb0070","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.bone.2019.01.003_bb0075","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1007\/s00198-016-3723-3","article-title":"Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment","volume":"27","author":"Trejo","year":"2016","journal-title":"Osteoporos. Int."},{"issue":"4","key":"10.1016\/j.bone.2019.01.003_bb0080","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/1078155207080806","article-title":"Significance and impact of bisphosphonate-induced acute phase responses","volume":"13","author":"Olson","year":"2007","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"1","key":"10.1016\/j.bone.2019.01.003_bb0085","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1359\/jbmr.2000.15.1.147","article-title":"Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations","volume":"15","author":"Pecherstorfer","year":"2000","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2019.01.003_bb0090","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study","volume":"20","author":"Gatti","year":"2005","journal-title":"J. Bone Miner. Res."},{"issue":"11","key":"10.1016\/j.bone.2019.01.003_bb0095","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1210\/jc.2015-2680","article-title":"Short-term safety of zoledronic acid in young patients with bone disorders: an extensive institutional experience","volume":"100","author":"George","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2019.01.003_bb0100","series-title":"Tietz Clinical Guide to Laboratory Tests","author":"Wu","year":"2006"},{"issue":"1","key":"10.1016\/j.bone.2019.01.003_bb0105","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/jbmr.1730","article-title":"Bone mineral content and density of the lumbar spine of infants and toddlers: influence of age, sex, race, growth, and human milk feeding","volume":"28","author":"Kalkwarf","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2019.01.003_bb0110","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/01.mph.0000162526.77400.78","article-title":"Cross-sectional study of bone mineral density in adult survivors of solid pediatric cancers","volume":"27","author":"Kelly","year":"2005","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.bone.2019.01.003_bb0115","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1210\/jc.2011-1111","article-title":"Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study","volume":"96","author":"Zemel","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.bone.2019.01.003_bb0120","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2214\/ajr.178.2.1780439","article-title":"Pediatric reference data for dual X-ray absorptiometric measures of normal bone density in the distal femur","volume":"178","author":"Henderson","year":"2002","journal-title":"AJR Am. J. Roentgenol."},{"issue":"2","key":"10.1016\/j.bone.2019.01.003_bb0125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jocd.2009.01.005","article-title":"Revised pediatric reference data for the lateral distal femur measured by Hologic Discovery\/Delphi dual-energy X-ray absorptiometry","volume":"12","author":"Zemel","year":"2009","journal-title":"J. Clin. Densitom."},{"issue":"4","key":"10.1016\/j.bone.2019.01.003_bb0130","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.nmd.2017.01.019","article-title":"Low bone mineral density and fractures are highly prevalent in pediatric patients with spinal muscular atrophy regardless of disease severity","volume":"27","author":"Wasserman","year":"2017","journal-title":"Neuromuscul. Disord."},{"issue":"4","key":"10.1016\/j.bone.2019.01.003_bb0135","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1080\/13638490600668061","article-title":"Fracture rate in children with cerebral palsy","volume":"9","author":"Stevenson","year":"2006","journal-title":"Pediatr. Rehabil."},{"issue":"10","key":"10.1016\/j.bone.2019.01.003_bb0140","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1515\/jpem-2016-0318","article-title":"A retrospective review of initial bisphosphonate infusion in an inpatient vs. outpatient setting for bisphosphonate naive patients","volume":"30","author":"Kreikemeier","year":"2017","journal-title":"J. Pediatr. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.bone.2019.01.003_bb0145","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.bone.2007.05.002","article-title":"Acute phase response and mineral status following low dose intravenous zoledronic acid in children","volume":"41","author":"Munns","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.01.003_bb0150","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bone.2017.02.003","article-title":"Unexpected widespread hypophosphatemia and bone disease associated with elemental formula use in infants and children","volume":"97","author":"Gonzalez Ballesteros","year":"2017","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2019.01.003_bb0155","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1067\/mpd.2002.128207","article-title":"Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial","volume":"141","author":"Henderson","year":"2002","journal-title":"J. Pediatr."},{"issue":"10","key":"10.1016\/j.bone.2019.01.003_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186941","article-title":"Lower incidence of fracture after IV bisphosphonates in girls with Rett syndrome and severe bone fragility","volume":"12","author":"Lambert","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.bone.2019.01.003_bb0165","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jocd.2005.11.003","article-title":"Pamidronate treatment and posttreatment bone density in children with spastic quadriplegic cerebral palsy","volume":"9","author":"Bachrach","year":"2006","journal-title":"J. Clin. Densitom."},{"issue":"2","key":"10.1016\/j.bone.2019.01.003_bb0170","first-page":"1016","article-title":"Low-dose pamidronate therapy for pediatric osteoporosis: influence of diagnosis on changes in fracture rate and bone mineral DENSITY","volume":"2","author":"Crossen","year":"2017","journal-title":"J. Pediatr. Child Health Care"},{"issue":"2","key":"10.1016\/j.bone.2019.01.003_bb0175","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1210\/jc.2010-0636","article-title":"Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"96","author":"Ward","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.bone.2019.01.003_bb0180","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1359\/jbmr.091007","article-title":"The relationship between fractures and DXA measures of BMD in the distal femur of children and adolescents with cerebral palsy or muscular dystrophy","volume":"25","author":"Henderson","year":"2010","journal-title":"J. Bone Miner. Res."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219300031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219300031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T18:59:50Z","timestamp":1550948390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328219300031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":36,"alternative-id":["S8756328219300031"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2019.01.003","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2019.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}